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Abstract
Background: Present technology uses mostly chimeric proteins as regulators and hormones or antibiotics as signals to
induce spatial and temporal gene expression.
Methodology/Principal Findings: Here, we show that a chromosomally integrated yeast ‘Leu3p-a-IRM’ system constitutes
a ligand-inducible regulatory ‘‘off-on’’ genetic switch with an extensively dynamic action area. We find that Leu3p acts as an
active transcriptional repressor in the absence and as an activator in the presence of a-isopropylmalate (a-IRM) in primary
fibroblasts isolated from double transgenic mouse embryos bearing ubiquitously expressing Leu3p and a Leu3p regulated
GFP reporter. In the absence of the branched amino acid biosynthetic pathway in animals, metabolically stable a-IPM
presents an EC50 equal to 0.8837 mM and fast ‘‘OFF-ON’’ kinetics (t50ON=43 min, t50OFF=2.18 h), it enters the cells via
passive diffusion, while it is non-toxic to mammalian cells and to fertilized mouse eggs cultured ex vivo.
Conclusions/Significance: Our results demonstrate that the ‘Leu3p-a-IRM’ constitutes a simpler and safer system for
inducible gene expression in biomedical applications.
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Introduction
Temporal and spatial control of gene activity is a fundamental
tool for regulated protein expression for basic, pharmaceutical and
clinical research [1,2,3]. The most popular inducible systems use
protein chimeras, antibiotics or hormones for induction and
include the tetracycline system [1], the systems of the recombina-
tion enzyme Cre/loxP [2] and Flipase [3], the EcR (ecdysone)
system [4] and the CRE-ER
T2 system based on the ligand-binding
domain of the estrogen receptor [5]. The ‘‘OFF/ON’’ gene
switches allow for the expression of cytotoxic and dominant
negative proteins [6], for the ability to reverse the expression of the
target gene [7], for the study of ‘‘gain of function’’ and ‘‘loss of
function phenotypes’’ [8] and for the ability to isolate protein
targets of transcription factors [9]. However, drawbacks include
the use of hormones and antibiotics as regulators of gene
expression, which result in cytotoxicity and developmental defects
in animal models, making it difficult to study the function of genes
involved in embryonic development [10], the high cost of the
inducer [11], leakiness in the absence of the inducer [12] and
chromosomal alterations [13]. As a result, development of tools
that allow for tighter control of gene induction with limited side
effects are necessary for gene function analysis in animal models
and safe clinical protocols for gene and stem cell therapy.
Leu3p belongs to the Zn(II)2-Cys6 cluster family[17,18]. Leu3p
is a pleiotropic transregulator with a molecular function
resembling that of the thyroid hormone receptors (TR) [14],
namely acting as an active repressor of transcription in the absence
(‘‘OFF’’) and as an activator in the presence (‘‘ON’’) of its ligand,
a-isopropylmalate (a-IRM), a metabolic intermediate of the
leucine biosynthetic pathway in yeast [15]. Leu3p binds with a
high affinity (Kd=3 nM) [16] to upstream promoter elements
(UASLEU) with a consensus everted repeat sequence 59-GCC-
GGNNCCGGC-39 [16] present in a number of genes involved in
branched amino-acid biosynthesis in yeast [18,21]. Leu3p consists
of four domains, the zinc cluster DNA binding domain located in
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[17], a linker region that specifies binding to the everted repeat
target site [23,24], an alpha-helix/heptad repeat domain from
amino acids 85–102 involved in dimerization [14] middle region
that is involved in the regulation of Leu3p activity (Ligand Binding
Domain) by a-IPM [19,23,25] and finally an acidic activation
domain from amino acids 856–886, self-masked in the absence of
a-IRM [19,26,27,28]. The mechanisms used by Leu3p as a
transcriptional regulator are conserved throughout plants and
mammals [18] and could involve TBP [30,31,32]. Leu3p is able to
transcribe genes solely and specifically in the presence of its
effector molecule a-IRM [17] in yeast, in transiently transfected
mouse pre-adipocytes [18] and fibroblasts [19] as well as in vitro
[15].
Here, we demonstrate that a chromosomally integrated
‘‘Leu3p-a-IRM’’ can be used as a highly specific inducible gene
expression system. Taking advantage of the fact that the leucine
biosynthetic pathway exists only in prokaryotes, fungi and superior
plants, but not in animals [20], we generated transgenic mice and
found that the ‘‘Leu3p-a-IPM’’ system is a safe and efficient
‘‘OFF-ON’’ gene switch in double transgenic primary mouse
embryo fibroblasts, thus paving the way for a number of
applications in gene regulation studies and biomedicine.
Results
Generation of transgenic mice and primary mouse
embryonic fibroblasts
To assess whether the ‘‘Leu3p-a-IPM’’ expression system is
functional in mice, we generated transgenic mice expressing
Leu3p ubiquitously under the control of the SV40 promoter (L3).
As a reporter, we have used GFP driven by four copies of the
Leu3p-dependent upstream activating sequence (UASLEU) en-
hancer positioned upstream of the thymidine kinase minimal
promoter (L3R) (Figure 1A). Leu3p binding to UASLEU should
actively repress the expression of GFP in the absence of a-IPM
and activate transcription in the presence of a-IPM [15]. We
obtained five transgenic lines expressing Leu3p ubiquitously
(ER2a-e) and another eight expressing the reporter GFP under
the control of Leu3p enhancer (ER4a-h) with variable degrees of
Figure 1. Generation of transgenic mice and primary mouse embryonic fibroblasts (pMEFs). (A) Top panel: scheme of the plasmid
constructs used for the generation of the L3 and L3R transgenic mouse lines. Lower panel: scheme of the cross between the transgenic mouse lines
and isolation of pMEFs from E13.5 mouse embryos. (B) PCR and RT-PCR analysis of mouse embryos showing Leu3 expression specifically in embryos
expressing L3 transgene. (C) RT-PCR analysis of pMEFs showing Leu3 expression in the cell lines isolated from L3 transgenic embryos and lack of GFP
expression in L3R pMEFs when a-IRM is not added in the culture. RT-PCR for GAPDH was used as a control. L3: Leu3 transgene/L3R: Leu3 reporter
transgene/E1-5: embryo 1/M1-5: pMEF cell line 1 (scale bar 200mm).
doi:10.1371/journal.pone.0012488.g001
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and L3R lines were set up, a-IPM was administered intraperito-
nially at day E7.5 for 2 days in 12 h intervals, the embryos were
harvested at E9.5 and E10.5 and assayed for fluorescence. None of
the embryos showed detectable GFP fluorescence signal (data not
shown). Thus, we could not assess, whether the GFP was not
functional with regard to fluorescence or the system was not
responding to a-IPM.
At that point, we decided to generate primary mouse fibroblasts
(pMEFs) from double transgenic E13.5 embryos and assay for the
function of the ‘‘Leu3p-a-IPM’’ system ex vivo. From timed L3 and
L3R matings, two double transgenic embryos (E3 and E4), one wt
embryo (E1), one embryo harboring the L3 transgene (E5) and one
embryo harboring the L3R transgene were harvested (E2). The
transgenes were identified using a polymerase chain reaction
(PCR) for the presence of the L3 and L3R constructs (Figure 1B,
L3 and L3R). To establish that the L3 transgene was indeed
expressing the Leu3 mRNA, we isolated total RNA from the E1-
E5 embryos and assayed for LEU3 mRNA expression in RT-PCR
experiments. This was evident in E3-E5 embryos that bore the L3
transgene, demonstrating that the LEU3 mRNA was indeed
expressed in those embryos (Figure 1B, LEU3).
Primary mouse embryonic fibroblasts (pMEFs) were then
isolated from the E1-E5 embryo trunks and cultured ex vivo (M1-
M5). As in the embryos, LEU3 expression was also evident in the
transgenic pMEFs isolated from L3 or L3/L3R transgenic
embryos (Figure 1C, M1-M3, M5). To assess whether the
‘‘Leu3p-a-IPM’’ was leaky, we then assayed for GFP expression
in pMEFs carrying the L3R transgene (M2 and M3). As
anticipated [15], no GFP expression was detected in the absence
of a-IPM (Figure 1C, GFP). Similar results were obtained with M4
pMEFs (data not shown). Thus, no leakiness was observed in the
absence of a-IPM in vivo and ex vivo (Figure 1).
‘‘Leu3p-a-IPM’’ acts as an ‘‘OFF-ON’’ genetic switch in
double transgenic primary mouse embryonic fibroblasts
To assess the permeability of a-IPM, mouse fibroblasts were
grown to confluency in the presence of variable amounts of
14C-a-
IRM supplemented with 2 mM non-radioactive a-IPM [16]. At
the end of the 48 hr incubation period, the cells were lysed and the
amount of
14C-a-IRM incorporated into the cells was counted.
The percentile of
14C-a-IRM incorporation was found to be
0.2860,039%, a value close to the theoretical one equal to 0.24%
when equilibrium is established between a fibroblast cell and the
milieu (Figure 2A; Table S1). Thus, we conclude that a-IPM is
passively diffused into mammalian cells and as a result no
additional yeast protein component is required for its entry into
the cells.
To evaluate the function of ‘‘Leu3p-a-IPM’’ as a gene switch,
we cultured wild type and transgenic pMEFs (M1-M3 and M5) for
12 hrs in the absence or presence of a-IPM at a final
concentration of 20 mM (Figure 2B, C). GFP expression was
detected using western blot (Figure 2B) and immunohistochemistry
(Figure 2C) experiments in pMEFs isolated from wild type (M1),
L3R (M2) and L3 (M5) transgenic embryos cultured either in the
absence (Figure 2B, lanes 1, 3, 5 and 7 and Figure 2C, i-ii, v-vi, ix-
x, xiii-xiv respectively) or presence of a-IPM (Figure 2B, lanes 2, 4,
6 and 8 and Figure 2C, iii-iv, vii-viii, xi-xii,xv-xvi respectively). In
accordance to the role of Leu3p as an active transcriptional
repressor [14], GFP expression was undetectable in pMEFs
isolated from L3 and L3R double transgenic embryos (M3) when
cultured in the absence of a-IPM (Figure 2B lane 7, Figure 2C,
xiii-xiv). These observations, demonstrate that indeed ‘‘Leu3p-a-
IPM’’ gene expression system is not leaky when its components are
chromosomally integrated. However, GFP protein was detected in
all M3 cells upon a-IPM induction, documented by GFP
immunoreactivity using a specific anti-GFP antibody both in
western blot (Figure 2B, lane 8) and immunofluorescence
(Figure 2C, xv-xvi) experiments. These results demonstrate that
the ‘‘Leu3p-a-IPM’’ is a tightly controlled gene expression system
in double transgenic pMEFs.
To study the kinetics of a-IPM, we assayed for the concentra-
tion of a-IRM required for optimal Leu3p-dependent induction of
GFP expression in double transgenic pMEFs, cultured in the
presence of increasing concentrations of a-IRM (0.078, 0.156,
0.312, 0.625, 1.25, 2.5, 5, 10, 15, 20 mM) and GFP protein was
detected and quantitated using indirect immunofluorescence
(Figure 2D). As a baseline for the assay, we recorded the GFP
expression in L3/L3R double transgenic pMEFs in the absence of
a-IPM and as negative controls corresponding values from L3R
and WT MEFs in the presence of increasing concentrations of a-
IRM (Table S2,). Consistent with previous observations obtained
in Figure 2B and 2C, background fluorescence was recorded from
WT, L3R treated with various concentrations of a-IRM and L3/
L3R pMEFS (Table S2). As expected, when a-IPM was added to
the media of the double transgenic L3/L3R pMEFs, the response
to increasing concentrations of a-IPM was recorded and the EC50
was calculated to be at 0.8837 mM (Figure 2D).
The time required for GFP induction was also analyzed in
double transgenic pMEFs. Cells were cultured in the presence of
either 5 or 20 mMa -IRM for different time points from 5 min to
48 hrs. GFP expression was detected and quantitated using
indirect immunofluorescence (Figure 2E). Induction of GFP
reaches half of its maximum level (a) 49 min after 5 mM a-IPM
addition (t50ON
5=4960.9 min) and (b) 43 min after 20 mM a-
IRM addition (t50ON
20=4363 min) and it increases proportion-
ally until it reaches a plateau 12 hrs after the addition of the
ligand.
Finally, the kinetics of reversibility after a-IPM withdrawal was
assayedforaperiodof48 hrs.Threehoursafterwithdrawalof5 mM
a-IRM, GFP levelsfalldown to 50% (t50OFF
5=3.6460.94 h), while
it takes two hours for GFP levels to fall down to 50% after withdrawal
of 20 mM a-IRM (t50OFF
20=2.1860.43 h). GFP levels continue to
drop within 48 hrsafter withdrawal (Figure 2F).Conclusively, there is
no need for an additional protein component or for specific receptors
in order for a-IPM to enter into mammalian cells, as a-IPM diffuses
passively into fibroblasts to specifically induce GFP expression with
fast ‘‘ON/OFF’’ kinetics.
a-IPM is not toxic to early mouse embryos
The effects of a-IPM on primary fibroblasts were benign. As
early embryos suffer from adverse effects of commonly used-
inducers, such as tamoxifen [21] and tetracycline [22], it was
important to explore any potential toxicity effects of a-IPM during
embryonic development in pregnant females and early embryos in
culture. Pregnant females were injected intraperitoneally on their
seventh day of pregnancy with 25 mM of a-IPM. All embryos
harvested at E11.5 were phenotypically normal, while mothers
themselves did not exhibit any abnormal phenotypes (data not
shown). Then, we assayed for the effects of a-IPM in early mouse
embryos. Two cell stage embryos (124 embryos in total) were
harvested and cultured in 4 groups for two days with 0, 5, 10 or
20 mM a-IPM (Figure 3A). In the absence of the inducer 61% of
the embryos reached the blastocyst stage. When embryos were
cultured in the presence of 5 or 10 mM of the inducer, similar
numbers reached the blastocyst stage (Figure 3B); however, all
embryos were arrested at the two-cell stage, when cultured at
20 mM a-IRM, attributed to either the sensitivity of these
‘‘Leu3p-a-IPM’’ Gene Switch
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(A) Incorporation of
14C-a-IPM into fibroblast cells. 10T1/2 were grown to confluency of 80–90% before they were incubated in the presence of a
constant amount a-IPM (2 mM) and various amounts of
14C-a-IPM (10–40 nM). After 48 hours, the cells were lysed in the presence of digitonin and
the radioactivity incorporated into the cell was counted. The average percent of
14C-a-IPM incorporated in the cells for each a-IPM concentration is
presented as the mean 6 standard deviation of the mean (SD) (Table S1). (B) and (C). Ex vivo analysis of ‘‘Leu3p-a-IRM’’ inducible gene expression
system in pMEFs. (B) Detection of GFP expression with western blot in primary fibroblasts in the presence or absence of a-IRM. b-actin expression
was used as a positive control. (C) Immunohistochemical detection of GFP expression in primary fibroblasts derived from the mating of L3 and L3R
transgenic lines. GFP expression is detected only upon a-IRM addition in the double transgenic fibroblasts. Results from GFP immunoreactivity
analysis are in accordance with the results obtained from western blot. (D) Kinetics of a-IRM. Titration of [a-IRM] for maximum inducibility in primary
mouse fibroblasts (pMEFs). WT, L3R and double transgenic pMEFS were cultured in the presence of increasing concentrations of a-IRM (0, 0.078,
0.156, 0.312, 0.625., 1.25, 2.5, 5, 10, 15, 20 Mm) and induced GFP was quantitated. Following data analysis performed using the GraphPad PRISM 5
software (GraphPad, Inc., USA), the EC50 was calculated to be 0.8837 mM. The data are derived from three independent experiments for each
experimental group (WT, L3R, L3/L3R) and for each different concentration of the inducer (0, 0.078, 0.156, 0.312, 0.625., 1.25, 2.5, 5, 10, 15, 20 Mm) and
the absolute values are presented (Table S2) as the mean 6 standard deviation of the mean (SD). (E) a-IRM ‘‘ON’’ kinetics. Double transgenic pMEFS
were cultured in the presence of 5 and 20 mMa -IRM for different time points. The time required for 50% of inducible GFP expression is t50’’ON’’
equal to 4960.9 min after 5 mM a-IPM addition and to 43+3 min after 20 mM a-IRM addition. (F) a-IRM ‘‘OFF’’ kinetics. Double transgenic pMEFs
were cultured in the presence of 5 and 20 mM a-IRM for 24 hrs, then a-IRM was removed from the media and cells were left in culture for a period
up to 48 hrs. After a-IPM removal from the media, the time required for 50% reduction of GFP expression is t50OFF
5 equal to 3.6460.94 h, when the
initial [a-IPM] concentration was 5 mM and t50OFF
20 equal to 2.1860.43 h, when the initial [a-IPM] concentration was 20 mM (scale bar: 50 mm). The
data are derived from three independent experiments for each experimental group.
doi:10.1371/journal.pone.0012488.g002
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toxicity effects created by the high levels of the inducer (Figure 3A
and B). Therefore, a-IPM provides for a wide range of
concentrations for inducibility with undetectable toxicity to
pregnant females and early embryos in vivo and ex vivo.
Discussion
Since the first transcriptional regulatory systems [24], several
novel inducible gene expression systems were developed which
have applications in gene function analysis [25], drug discovery
[26], gene therapy [27] and engineering of desired phenotypes
during development and in adult life [28]. An ideal regulatory
system should be a) activated by a specific non-toxic bioavailable
exogenous ligand, b) inactivated when the ligand is not present or
removed from the media and c) its should not interfere with
endogenous mammalian gene expression and metabolic pathways.
We have developed a novel heterologous inducible gene expres-
sion system, based on a yeast transcription factor Leu3p, namely
Leu3p-a-IRM that meets these criteria.
a-IPM functions as an intermediate during leucine biosynth-
esis in yeast and activates specifically Leu3p-dependent tran-
scription, both in vivo [29] and in vitro [15] and in mammalian
cells [18] (Figure 2B,C). Compared to commonly used inducers
tamoxifen [21] and tetracycline [22,30] that can cause adverse
effects during development, a-IPM is an ideal molecular
matchmaker since it lacks toxicity (Figure 2 and 3), has metabolic
stability [20] and lipid solubility (Figure 2A). The fact that a-
IPM functions as an inducer of Leu3p activity in yeast extracts
[17], in mouse pre-adipocytes [18], in mouse fibroblasts
(Figure 2A) and in double transgenic pMEFs (Figure 2B–F) in
a range of concentrations with no additional yeast component
required for its function demonstrates that a-IPM can act as a
safe highly specific ligand.
Another advantage of the ‘‘Leu3p-a-IPM’’ system is the tight
regulation of Leu3p-inducible promoters by active repression
exerted by Leu3p in the absence of a-IPM [17]. Leu3p can
associate with the DNA in the absence (repressor form) and the
presence (activator form) of a-IPM in vivo, but transcriptional
activation is exerted only in the presence of a-IPM [18]. Thus, in
the absence of a-IPM, regulated genes are suppressed; in the
presence of a-IPM, they are activated, as we have also
demonstrated in chromosomally integrated components of the
system in primary mouse fibroblasts (Figure 2B and C). This is due
to the high binding affinity of Leu3p to the UASLEU3p elements
(Kd=3 nM) [16] without the need for specific partners, a
drawback for inducible gene expression systems, and involves a
self-masking mechanism for the activation domain [19,28]. Our
results in transgenic pMEFs confirm that ‘‘Leu3p a-IPM’’ switch is
not leaky (Figures 1B and C, 2B and C), in accordance with the
function of Leu3p as a transcriptional repressor in the absence of
a-IRM [17,18,20,22]. We also demonstated that removal of a-
IPM from the culture of double transgenic primary mouse
fibroblasts results in the repression of GFP expression with rapid
kinetics compared to other inducible gene expression systems, such
as tetracycline and FK506/rapamycin inducible systems with slow
induction and reversibility kinetics [31]. This feature will allow us
to use this system efficiently for time-dependent and tissue-specific
expression of any protein of interest bypassing toxicity and early
lethality events due to non-specific or leaky expression.
Figure 3. a-IPM toxicity in early mouse embryos. Two cell stage embryos were harvested from F1 pregnant females and cultured for two days
ex vivo in the presence of increasing concentrations of a-IPM (0, 5, 10 or 20 mM) until they reach the blastocyst stage. Thirty one embryos were used
for every experimental group. (A) Bright field photographs of embryos cultured for two days under different concentrations of a-IRM. In the
presence of a-IRM in concentrations of 5 and 10 mM, two cell stage embryos develop normally to blastocyst stage compared to the control.
However, early mouse embryos cultured in the presence of 20 mM a-IRM arrest at the 2-cell stage due to osmolarity changes. (scale bar 50mm) (B)
Assessment of a-IPM toxicity in early mouse embryos ex vivo.
doi:10.1371/journal.pone.0012488.g003
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mammals greatly facilitates the use of the ‘‘Leu3p-a-IPM’’system as
a general transcriptional ‘OFF-ON’ switch in animals. The fact that
its components fail to evoke an immune response and it enables
seamless integration into the regulatory and metabolic network of
the target cell is very important since it demonstrates that the
mechanisms of gene expression tangled with Leu3p are conserved
throughout evolution from yeast to mammals [14]. Furthermore,
beyond known components of the basal transcriptional machinery
[30,31,32], the presence of other species-specific proteins is not
necessary in order for ‘‘Leu3p-a-IPM’’ to activate gene expression,
in contrast to Gal4:Gal80, in which galactose induces the release of
Gal80 [32] and to ER-based HSP90:CreER
T2 system, in which
tamoxifen induces the dissociation of HSP90 promoting the nuclear
translocation of CreER
T2 protein [33]. Furthermore, there is no
need for the generation of fusion proteins in order for ‘‘Leu3p-a-
IPM’’ to be functional (37). Finally, ‘‘Leu3p-a-IPM’’ provides for a
range of expression levels from no expression to high levels in
response to the inducer that can support platforms for tissue- or
target-specificinterventions.Nevertheless,the needstillexistsforthe
discovery of analogues for a-IPM to be used in nM and mM
concentrations to overcome adverseosmolarity and possible toxicity
effects in high concentrations.
Overall, we show that ‘‘Leu3p-a-IPM’’ is a purely heterologous
inducible regulatory ‘‘OFF/ON’’gene switch with an extensive
dynamic action area that provides specificity, lack of interference
to known cellular pathways in animals, lack of toxicity, fast
inducibility and reversibility, bioavailability and dose–dependence.
These advantages pave the way for applications of the ‘‘Leu3p-a-
IPM’’ gene switch for a wide range of developmental studies,
inducible gene targeting and transgenesis in mice and other
organisms, drug discovery, gene therapy and stem cell therapy.
Materials and Methods
DNA constructs
SV40-Leu3 expression construct (L3) was generated by cloning
the Leu3 cDNA, as an EcoRI-BamHI fragment into the p513
vector (a gift from D. Metzger) from the pMSV-Leu3 vector (Guo,
1990). L3 transgenic construct was isolated as an XhoI-XbaI
fragment. A (UASLEU)4-tk-LUC plasmid was initially generated by
the insertion of a 100 bp double-stranded oligonucleotide harbor-
ing four UASLEU sequences behind the thymidine kinase minimal
promoter into the pTK luciferase vector (a gift from Vincent
Giguere). The (UASLEU)4-tk fragment was cloned behind the
mmGFP5 cDNA in the pG1 vector (a gift from Darren Gilmour).
(UASLEU)4-tk-GFP (L3R) transgenic construct was isolated as a
NotI-HindIII fragment.
14C-a-IRM incorporation
Fibroblasts were incubated in the presence of a constant amount
(2 mM) a-IRM and variable amounts of
14C-a-IRM (10, 20,30
and 40 nM) until they reach confluency. Cells were lysed and the
incorporated radioactivity from the lysed cells was counted in a
scintillation counter. For each experimental group with different
amounts of
14C-a-IRM, two different samples were recorded and
the average percent of radioactivity incorporated in the cells are
presented in Table S1.
Transgenic mice
Linearized DNA (L3 and L3R) was microinjected in pronuclei
of fertilized egg. For L3 construct five founders were generated
(ER2a-e) (germline transmission 25–50%). For L3R construct
eight founders were generated (ER4a-h) (germline transmission in
ER4a-c and ER4g 20–50%). All animals were handled in strict
accordance with good animal practice as defined by the Animals
Act 160/03.05.1991 applicable in Greece, revised according to the
86/609/EEC/24.11.1986 EU directive regarding the proper care
and use of laboratory animals and in accordance to the Hellenic
License for Animal Experimentation at the BSRC’’ Alexander
Fleming’’ (Prot. No. 767/28.02.07) issued after protocol approval
by the Animal Research Committee of the BSRC ‘‘Alexander
Fleming’’ (Prot. No. 2762/03.08.05).
Isolation of primary mouse embryonic fibroblasts
(pMEFs)
E13.5 mouse embryos from L3R male to L3 female intercrosses
were harvested and dissected in DMEM media. Heads were used
for RNA preparation. Internal organs were used for genotyping.
Carcasses were washed twice in PBS, minced finely, pieces were
dissociated for 10 min with rotation at 37uC using trypsin/EDTA
solution, triturated and filtered through a 70 mm mesh. Cells were
plated in 10 cm tissue culture dishes (1 cultured dish per embryo)
in standard media.
Genotyping
Transgenic mice, embryos and pMEFs were genotyped by PCR
(T=62uC).
L3 (ER2c):59CGAGGAGAACCTATTTCTTACAGTACCA39
(L3-1003F) and, 59TGATAATCGAGTCATTAAGTCTGTAG-
CCC39 (L3-1348R) (345 bp).
L3R (ER4a): GFP-45F 59CTGGAGTTGTCCCAATTCTT-
GTTG 39 (forward) and GFP-428R 59GATGTTTCCGTCCTC-
CTTGAAATC39 (reverse) (383 bp).
RT-PCR
Total RNA was isolated with TriZol (Invitrogen) and RT-PCR
was carried out using the Qiagen One-Step RT-PCR system. The
following primers were used: for GAPDH (T=57uC): 59-CA-
TCTCTGCCCCCTCTGCTG-39 (forward) and 59-CGACGC-
CTGCTTCACCACCT-39 (reverse); for Leu3 (T=60uC): 59-CG-
AGGAGAACCTATTTCTTACAGTACCA-39 (forward) and 59-
TGATAATCGAGTCATTAAGTCTGTAGCCC-39 (reverse) for
GFP (T=62uC) : GFP-45F 59CTGGAGTTGTCCCAATTCTT-
GTTG 39 (forward) and GFP-428R 59GATGTTTCCGTCCT-
CCTTGAAATC39 (T=62uC). The size of the amplified products
was 440 bp, 345 bp and 383 bp respectively.
a-IPM preparation
A 500 mM stock solution of (+)-2-a-isopropylmalic acid (a-IPM)
(Sigma-Aldrich, Taufkirchen, Germany) was prepared in ddH20
and the pH was adjusted to 7.0 with 10N KOH.
Immunohistochemistry
Transgenic pMEFs were fixed in 4% paraformaldehyde in
0.12 M PB, pH 7.2 at 4uC for 5 min and incubated in blocking
buffer (BB) (0. 12 M PB, pH 7.2, 0.15% glycine, 2 mg/ml BSA
fragment V (Gibco-Invitrogen, Thessaloniki, Greece) and 0.1%
Triton X-100) for 1 h on ice. Cells were incubated o/n at 4uC
with an anti-GFP rabbit polyclonal antibody (Santa Cruz
Biotechnology Inc., Heidelberg, Germany) in 1:1000 dilution
in BB. After extensive washes with PBS at RT, cells were
incubated with secondary antibody (Alexa 488-conjugated anti-
rabbit, 1:500) (Molecular Probes-Invitrogen, Thessaloniki,
Greece) for 1 h at RT. Samples were stored in anti-fade DAPI
mounting media (Molecular Probes - Invitrogen, Thessaloniki,
Greece).
‘‘Leu3p-a-IPM’’ Gene Switch
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12488Western Blotting
Cells were harvested with trypsin, pellet was washed with PBS
and dissolved in cold buffer A (20 mM Tris-HCl, 420 Mm NaCl,
0.2 Mm EDTA, 0.5 mM DTT, 25% glycerol, 0.5 mM PMSF,
1.5 mM MgCl2, 0.5% NP40) supplemented with Protease
Inhibitor Cocktail (Sigma-Aldrich, Taufkirchen, Germany). In-
cubation at 4uC for 15 min and centrifuge for 15 min at 10,0006g
followed. Protein concentration of the supernatant was determined
by Bradford assay. Proteins (20mg per lane) were separated on
10% SDS-polyacrylamide gel, transferred to nitrocellulose mem-
brane and membrane was blocked in western blot blocking buffer
(5% milk, 10 mM Tris-HCl pH 7.6, 0.15 mM NaCl, 0.05%
Tween-20) for 2 h at RT, incubated o/n with the primary
antibody at 4uC. Goat anti-GFP polyclonal antibody (Santa Cruz
Biotechnology, Inc, Santa Cruz, CA,U.S.A) and goat b-actin
polyclonal antibody (Cell Signaling Technology, Inc, Danvers,
MA,USA) were used (1:1000). After extensive washing in TBST.1
(10 mM Tris-HCl, 0.15 mM NaCl, 0.1% Tween-20), goat anti-
rabbit HRP conjugated secondary antibody was applied (1:10,000)
for 2 h at RT. Proteins were visualized by chemiluminescence
detection using ECL (Cell Signaling Technology, Inc., Danvers,
MA,USA).
a-IPM toxicity effects in pregnant mice and early mouse
embryos
a-IPM (25 mM) was injected into pregnant females intraper-
itonially at the seventh day of pregnancy and embryos were
harvested at E11.5. No obvious abnormalities were detected. To
assay a-IPM toxicity effects in early mouse embryos, fertilized eggs
in the two-cell stage where harvested from pregnant F1 females
and incubated in KSOM media with variable concentrations of a-
IPM (0–20 mM) ex vivo for two days until they reach the blastocyst
stage.
Quantitation of GFP protein
The levels of induced GFP protein after indirect immunofluor-
escence using an anti-GFP antibody were quantified in double
transgenic pMEFs in a Fluorescence plate reader TECAN Infinite
M200 (wavelength range of 488 nm–522 nm).
Supporting Information
Table S1 Average percent of 14C-a-IRM incorporated in
fibroblast cells.
Found at: doi:10.1371/journal.pone.0012488.s001 (0.03 MB
DOC)
Table S2 Response to increasing a-IRM concentrations re-
corded from wt, L3R and L3/L3R pMEFs.
Found at: doi:10.1371/journal.pone.0012488.s002 (0.05 MB
DOC)
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